IRWD Stock Cash Flow Statements

Ironwood Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Ironwood Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-06-30	2014-03-31	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31

cash flows from operating activities:
net income	23,599,000	-37,386,000	2,256,000	3,646,000	-860,000	-4,162,000	-1,745,000	13,950,000	-1,089,478,000	45,714,000	48,867,000	50,317,000	37,080,000	38,801,000	41,374,000	55,845,000	391,303,000	39,926,000	43,204,000	34,423,000	25,204,000	3,345,000	47,858,000	20,648,000	12,283,000	-59,284,000	-15,493,000	-174,351,000	-49,380,000	-43,144,000	-44,224,000	-52,501,000	-13,505,000	-33,204,000	-21,702,000	-13,297,000	-47,390,000	-48,020,000	-33,222,000	-60,357,000	-49,626,000	-65,149,000	-93,902,000	47,635,000	-40,803,000	-35,601,000	-20,633,000	-18,844,000	-18,401,000	-6,747,000	-17,209,000	-16,253,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	467,000	479,000	485,000	507,000	506,000	513,000	512,000	507,000	270,000	286,000	340,000	363,000	360,000	355,000	359,000	358,000	396,000	410,000	421,000	1,821,000	640,000	682,000	867,000	3,174,000	297,000	1,242,000	1,265,000	1,386,000	1,671,000	1,790,000	1,928,000	2,910,000	2,761,000	2,198,000	2,487,000	2,833,000	2,788,000	3,152,000	2,891,000	3,085,000	3,126,000	2,789,000	2,788,000	3,032,000	2,810,000	2,680,000	2,286,000	2,904,000	2,133,000	1,440,000	1,502,000	1,303,000
loss on disposal of property and equipment			0	5,000	37,000	33,000									0	76,000	0	17,000		45,000	407,000	16,000																			53,000					1,000				22,000	222,000	5,000
share-based compensation expense	4,524,000	5,291,000	4,566,000	8,329,000	8,570,000	8,385,000	8,704,000	7,906,000	8,264,000	7,131,000	7,291,000	7,067,000	6,601,000	6,089,000	6,090,000	6,206,000	4,589,000	5,396,000	10,008,000	7,712,000	7,091,000	6,364,000	5,486,000	5,521,000	5,283,000	14,988,000	11,215,000	12,968,000	10,751,000	9,043,000	9,140,000	7,279,000	7,383,000	6,933,000	8,097,000	6,806,000	6,640,000	6,903,000	5,426,000	6,012,000	6,074,000	4,817,000	5,275,000	5,135,000	4,056,000	3,721,000	2,862,000	2,951,000	2,698,000	1,838,000	1,690,000	1,608,000
non-cash interest expense	416,000	416,000	415,000	350,000	550,000	589,000	587,000	586,000	485,000	402,000	400,000	400,000	516,000	537,000	6,148,000	6,037,000	5,928,000	5,822,000	5,718,000	5,615,000	5,514,000	5,416,000	4,058,000	6,232,000	4,691,000	4,609,000	4,557,000	4,453,000	4,352,000	4,239,000	3,972,000	3,877,000	3,831,000	3,760,000	3,649,000	3,572,000	3,429,000	800,000	370,000	402,000	386,000	484,000	453,000
non-cash lease expense	418,000	409,000
deferred income taxes	14,105,000	670,000	41,104,000	7,681,000	13,255,000	6,050,000	31,321,000	14,256,000	10,008,000	17,052,000	20,129,000	16,016,000	14,886,000	14,708,000	1,933,000	2,573,000
changes in assets and liabilities:
accounts receivable	-46,400,000	42,118,000	-5,684,000	-18,095,000	13,908,000	57,107,000	-4,577,000	-5,556,000	-3,241,000	14,298,000		-14,338,000	3,012,000	18,382,000																																543,000	1,886,000					511,000
prepaid expenses and other current assets	-64,000	-407,000	2,268,000	357,000	71,000	-2,607,000	6,101,000	4,387,000	-2,599,000	-3,669,000	1,646,000	2,842,000	-1,317,000	53,000	1,633,000	2,069,000	-1,420,000	-1,681,000	1,585,000	3,568,000	-3,939,000	301,000	-625,000	-3,068,000	166,000	2,481,000	9,743,000	-3,791,000	-7,726,000	-1,647,000	331,000	372,000	-146,000				46,000	2,193,000	483,000		938,000						1,762,000	-359,000	1,021,000
other assets	143,000	141,000	117,000	38,000	-1,039,000	30,000	35,000	-84,000	-297,000	27,000	16,000	9,000	83,000	45,000	-146,000	25,000	45,000	19,000	-62,000	-61,000	21,000	-51,000			-64,000	58,000	594,000	64,000	37,000	62,000	45,000	201,000	-26,000	860,000	425,000	385,000						52,000	20,000	20,000	50,000	14,000	22,000	37,000	23,000
accounts payable and accrued expenses	-13,836,000	9,662,000	-5,752,000	69,000	-1,999,000	-12,526,000	-12,547,000	6,594,000	17,628,000	705,000		4,657,000	-3,648,000	-7,117,000																													8,897,000	-3,402,000						2,610,000
accrued research and development costs	-1,610,000	-1,054,000	-2,727,000	2,688,000	-5,160,000	-9,451,000	5,595,000	-9,387,000	301,000	-2,384,000	-415,000	-665,000	896,000	-10,454,000	14,221,000	37,000	384,000	-644,000	-759,000	257,000	114,000	-670,000	-1,504,000	-1,314,000	820,000	1,515,000	3,131,000	-290,000	705,000	-2,640,000	2,348,000	-1,831,000	-1,105,000	1,389,000	28,000	2,380,000		-3,740,000	5,696,000				520,000			948,000
operating lease liabilities	-584,000	-572,000	-562,000	-554,000	-537,000	-523,000	-516,000	-509,000	-491,000	-479,000	-473,000	-496,000	-495,000	-483,000	-476,000	-468,000	-451,000	-440,000	-433,000	58,000	299,000	294,000	-9,366,000	2,005,000	-1,856,000	-2,829,000
other liabilities	3,669,000	187,000	-21,674,000	4,471,000	5,778,000	1,169,000	-3,006,000	-554,000	3,309,000	758,000	2,090,000	2,736,000	2,382,000	3,616,000	-1,101,000	111,000	-147,000	-133,000	1,247,000	-85,000	-104,000	-29,000
net cash from operating activities	-15,068,000	19,954,000	15,214,000	9,885,000	33,465,000	44,985,000	35,834,000	32,459,000	34,963,000	80,171,000	79,182,000	69,092,000	61,365,000	64,124,000	64,568,000	75,065,000	48,568,000	73,694,000	51,513,000	53,632,000	20,088,000	43,603,000				-42,385,000	9,273,000	-26,578,000	-22,691,000	-30,886,000	-31,261,000	-27,846,000	-18,686,000			161,000
capex	-2,000	-31,000	0	-16,000	-58,000	-68,000	-211,000	-49,000	0	-13,000	27,000	-66,000	-88,000	-9,000	0	0	0	0	0	0	-376,000	-1,438,000				-3,235,000	-3,301,000	-2,120,000	-1,691,000	-1,509,000	-709,000	-1,037,000	-1,198,000			0
free cash flows	-15,070,000	19,923,000	15,214,000	9,869,000	33,407,000	44,917,000	35,623,000	32,410,000	34,963,000	80,158,000	79,209,000	69,026,000	61,277,000	64,115,000	64,568,000	75,065,000	48,568,000	73,694,000	51,513,000	53,632,000	19,712,000	42,165,000				-45,620,000	5,972,000	-28,698,000	-24,382,000	-32,395,000	-31,970,000	-28,883,000	-19,884,000			161,000
cash flows from investing activities:
purchases of property and equipment	-2,000	-31,000	0	-16,000	-58,000	-68,000	-211,000	-49,000	0	-13,000	27,000	-66,000	-88,000	-9,000							-376,000	-1,438,000	-2,668,000	-3,077,000	1,791,000	-3,235,000	-3,301,000	-2,120,000	-1,691,000	-1,509,000	-709,000	-1,037,000	-1,198,000
net cash from investing activities	-2,000	-31,000	0	-16,000	-58,000	-68,000	-4,188,000	-22,625,000	-999,492,000	-13,000	27,000	-66,000	-88,000	-9,000					-28,000	0	-376,000	-1,438,000	-2,661,000	-3,077,000	-2,429,000	-2,977,000	17,488,000	14,285,000	12,440,000	44,653,000	70,595,000	88,059,000	-115,424,000	-90,361,000	4,763,000	23,348,000			19,761,000							1,288,000
cash flows from financing activities:
proceeds from exercise of stock options and employee stock purchase plan	88,000	6,000	203,000	0	749,000	10,061,000	998,000	12,000			2,806,000	797,000	4,315,000	1,622,000	5,544,000	6,164,000	5,662,000	2,211,000	3,524,000	670,000	2,397,000	11,955,000	6,447,000	1,944,000	1,717,000	3,487,000	4,909,000	8,108,000	12,841,000	6,203,000	10,302,000	8,171,000	14,288,000	4,390,000	4,322,000	1,841,000	933,000	2,995,000	7,946,000	7,212,000	3,852,000	3,425,000	3,090,000	538,000
taxes paid related to net share settlement of share-based awards			0	0	-121,000	-616,000
repayment on 2024 convertible notes
proceeds from revolving credit facility			0	0			0	0
repayments of revolving credit facility			-15,000,000	-25,000,000	0	-25,000,000	-25,000,000
net cash from financing activities	88,000	6,000	-14,887,000	-27,156,000	-49,372,000	-15,555,000	-50,904,000	-74,988,000	399,071,000	3,981,000	2,806,000	797,000	-150,283,000	-90,873,000	-18,587,000	6,164,000	5,662,000	2,211,000	3,524,000	670,000	2,397,000	11,955,000		8,633,000	-7,500,000	-8,765,000	4,849,000	7,810,000	12,128,000	5,285,000	9,479,000	19,102,000	5,177,000				-3,975,000	303,971,000	5,418,000	6,963,000	194,005,000	141,116,000	170,300,000	469,000	1,333,000	86,104,000	565,000	1,349,000	599,000	-581,000	-314,000	203,109,000
effect of exchange rate changes on cash and cash equivalents	-647,000	-7,000
net increase in cash and cash equivalents	-15,629,000	19,922,000																													48,813,000	79,315,000	-128,933,000	-94,395,000	-3,594,000	19,639,000	-8,373,000			-109,772,000	129,639,000					44,330,000	20,635,000	1,971,000	1,893,000
cash and cash equivalents, beginning of period	0	88,559,000																													0	54,004,000	0	0	0	261,287,000	0	0	74,297,000	0	75,490,000	0	136,700,000	0	0	87,282,000	0	0	44,321,000	-839,000	0	123,145,000
cash and cash equivalents, end of period	-15,629,000	108,481,000																													48,813,000	133,319,000	-128,933,000	-94,395,000	-3,594,000	280,926,000	-8,373,000	192,758,000	63,692,000	-109,772,000	205,129,000	114,159,000	105,302,000	38,784,000	-44,529,000	131,612,000	20,635,000	1,971,000	46,214,000	23,312,000	-40,954,000	76,338,000

change in fair value of note hedge warrants							0	0	0	-19,000	18,000	-151,000	-747,000	-417,000	-4,173,000	-5,572,000	3,082,000	-4,109,000	4,393,000	-5,263,000	751,000	-12,053,000	15,492,000	-15,688,000	10,803,000	5,625,000	-89,015,000	-20,241,000	46,890,000	3,941,000	16,034,000	20,187,000	-6,884,000	33,283,000
acquired in-process research and development							5,000,000	0
operating lease right-of-use assets			402,000	393,000	385,000	378,000	370,000	363,000	355,000	349,000	342,000	335,000	328,000	322,000	316,000	309,000	304,000	297,000	292,000	288,000	291,000	296,000	2,050,000	5,776,000	2,849,000	3,466,000
acquisition of vectivbio holding ag, net of cash acquired							-3,977,000	-22,576,000
purchase of subsidiary shares from noncontrolling interests
repayment of 2024 convertible notes			0
repayment of 2022 convertible notes
costs associated with revolving credit facility			-90,000				-591,000	0
repurchases of common stock											0	0	-33,899,000	-92,495,000
effect of exchange rate changes on cash, cash equivalents and restricted cash			21,000	-26,000	-51,000	24,000	-50,000
net increase in cash, cash equivalents and restricted cash					-16,016,000	29,386,000			-565,458,000	84,139,000	82,015,000	69,823,000	-89,006,000	-26,758,000	45,853,000	81,092,000	54,230,000	75,905,000	55,009,000	54,302,000	22,109,000	54,120,000	31,366,000	40,323,000	-19,166,000	-54,127,000	31,610,000	-4,483,000	1,877,000	19,052,000
cash, cash equivalents and restricted cash, beginning of period			0	0	0	92,154,000	0	0	0	657,938,000	0	0	0	621,864,000	0	0	0	364,784,000	0	0	0	179,244,000	0	0	0	180,848,000	0	0	0	132,792,000
cash, cash equivalents and restricted cash, end of period			348,000	-17,313,000	-16,016,000	121,540,000	-19,308,000	-65,157,000	-565,458,000	742,077,000	82,015,000	69,823,000	-89,006,000	595,106,000	45,853,000	81,092,000	54,230,000	440,689,000	55,009,000	54,302,000	22,109,000	233,364,000	31,366,000	40,323,000	-19,166,000	126,721,000	31,610,000	-4,483,000	1,877,000	151,844,000
reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
cash and cash equivalents			348,000	-17,313,000	-16,016,000	121,540,000	-18,010,000	-65,157,000	-565,021,000	740,342,000	82,015,000	69,823,000	-89,006,000	593,371,000	45,853,000	81,577,000	54,230,000	438,469,000		54,303,000	22,109,000	231,143,000	37,792,000	40,323,000	-20,137,000	119,045,000	31,610,000	-3,853,000	627,000	144,788,000
restricted cash								0	-437,000	1,735,000	0	0	0	1,735,000	0	-485,000	0	2,220,000		-1,000	0	2,221,000	-6,426,000	0	971,000	7,676,000	0	-630,000	1,250,000	7,056,000			0	0													0	0	2,833,000			269,000
total cash, cash equivalents, and restricted cash			348,000	-17,313,000	-16,016,000	121,540,000	-19,308,000	-65,157,000	-565,458,000	742,077,000	82,015,000	69,823,000	-89,006,000	595,106,000	45,853,000	81,092,000	54,230,000	440,689,000		54,302,000	22,109,000	233,364,000	31,366,000	40,323,000	-19,166,000	126,721,000	31,610,000	-4,483,000	1,877,000	151,844,000
supplemental cash flow disclosure:
cash paid for interest																																												-8,000	12,000	12,000	12,000	20,000	15,000	128,000	84,000	96,000
cash paid for income taxes
non-cash investing and financing activities
stock option exercise proceeds receivable in other current assets
net decrease in cash, cash equivalents and restricted cash
reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
change in fair value of convertible note hedges											0	0	1,428,000	-313,000	6,739,000	3,408,000	84,000	1,719,000	-4,813,000	7,879,000	-284,000	15,519,000	-20,009,000	20,454,000	-10,131,000	-9,569,000	101,754,000	16,752,000	-46,081,000	-5,257,000	-21,371,000	-17,988,000	4,781,000			8,778,000	17,820,000
stock repurchases payable in accrued expenses
payment on 2022 convertible notes											0	0
proceeds from exercise of stock options										3,981,000																																				945,000
accounts receivable and related party accounts receivable															-12,415,000	333,000	-15,243,000	35,037,000	-9,305,000	-8,073,000	-14,472,000	35,941,000	-22,181,000	-25,183,000	-29,862,000	8,333,000	-15,575,000	15,144,000	-9,868,000	11,506,000	-9,210,000	13,707,000	-11,139,000	-568,000	-129,000	1,500,000							1,439,000
inventory																			0	0				-451,000	-483,000	-152,000	-93,000	279,000	-224,000	-768,000	1,010,000	71,000						0	4,000
accounts payable, related party accounts payable, and accrued expenses
deferred revenue																							-403,000								-516,000	741,000	-4,127,000			320,000
gain on lease modification																							0	0
settlement on non-cancellable purchase commitments
loss on extinguishment of debt																							0								0	2,009,000
accounts payable, related party accounts payable and accrued expenses															4,066,000	3,718,000	-2,486,000	-7,942,000	890,000	5,448,000	-2,093,000	-11,768,000	4,575,000	-12,070,000	-11,751,000	-13,454,000	10,823,000	-9,042,000	18,576,000	-12,300,000	-107,000	-5,238,000	3,382,000
net cash from continuing operating activities																			51,513,000	53,632,000	20,088,000	43,603,000	27,580,000	34,767,000
net cash from discontinued operating activities																							0	0
proceeds from sale of property and equipment																							7,000	0	3,000	258,000	936,000	355,000	239,000	33,000	36,000	43,000	224,000				10,000	4,000	23,000							4,000
net cash (used in) continuing investing activities
net cash (used in) discontinued investing activities
net cash (used in) investing activities
proceeds from issuance of convertible senior notes																							0														0
purchase of capped calls																							0
proceeds from partial termination of convertible note hedges and note hedge warrants
costs associated with issuance of convertible senior notes																							0
payments for partial repurchase of 2022 convertible notes																							0
payments on 8.375% notes due 2026
recognition of asset retirement obligation
fixed asset purchases in accounts payable and accrued expenses
purchase of property and equipment
amortization of acquired intangible assets																											0	1,159,000	3,476,000	3,476,000
impairment of intangible assets																											0
gain on disposal of property and equipment																							37,000	0	-477,000	586,000				-34,000
write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments																							0
write-down of excess non-cancellable zurampic and duzallo sample purchase commitments																											0	0
accretion of discount/premium on investment securities																											-8,000	-19,000	-20,000	-118,000	6,000	105,000	106,000	104,000	117,000	340,000	424,000	137,000	161,000	330,000	136,000	500,000	387,000	261,000	270,000	309,000	509,000	615,000	727,000	408,000	389,000	98,000
non-cash change in fair value of contingent consideration																											0	-33,519,000	1,962,000	512,000	6,933,000	1,614,000	1,164,000
deferred rent																											200,000	60,000	203,000	453,000	578,000	-3,555,000	-2,035,000																	666,000	6,581,000	233,000
purchases of available-for-sale securities																											0	-750,000	0	-2,491,000	-45,929,000	-44,777,000	-147,887,000
sales and maturities of available-for-sale securities																											19,853,000	16,800,000	13,892,000	48,620,000	117,197,000	133,830,000	33,437,000	21,623,000	105,378,000	76,985,000	73,012,000	45,000,000	94,006,000	47,451,000	74,518,000	80,852,000	13,290,000	19,110,000	20,960,000	29,265,000	70,489,000	38,475,000	68,111,000	91,870,000
net cash from continuing investing activities																			-28,000	0	-376,000	-1,438,000	-2,661,000	-3,077,000
net cash from discontinued investing activities																							0	0
payments on capital lease obligations
payments on contingent purchase price consideration																											-58,000	14,000	-30,000	-91,000	0	-56,000
net cash from continuing financing activities																			3,524,000	670,000	2,397,000	11,955,000	6,447,000	8,633,000
net cash from discontinued financing activities
write-down of commercial supply and inventory to net realizable value and settlement on non-cancellable purchase commitments
payments on 2026 notes																							0
gain on facility subleases
principal payments on pharma notes																															0	-134,258,000	-8,405,000
costs associated with issuance of 2026 notes																															-26,000	-209,000	-46,000
proceeds from issuance of 2026 notes, net of discount to lender																															0	146,250,000
net cash (used in) provided financing activities
purchases under capital leases																																												127,000	0	120,000	0	0	325,000	42,000
extinguishment of capital leases
net cashed used in operating activities																								34,767,000
proceeds from partial termination of convertible note hedges and warrants
write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments
principal payments on 2026 notes																									-9,217,000	-12,252,000
(gain) loss on disposal of property and equipment																											-276,000	-1,316,000
payment for acquisition of lesinurad license																																	0
contingent consideration																																	-28,375,000	8,611,000
payments on capital leases																												-312,000	-683,000	-827,000	-797,000	-796,000	-660,000
write-down of excess non-cancellable zurampic sample purchase commitments
amortization of acquired intangible asset																															421,000	420,000	-3,297,000	3,213,000
write-down of excess non-cancelable zurampic sample purchase commitments																															0	1,353,000
write-down of lesinurad commercial supply to net realizable value and loss on non-cancellable purchase commitments
(gain) loss on facility subleases																															0	-1,579,000
non-cash investing activities
write-down of inventory to net realizable value and loss on non-cancellable purchase commitments
loss on facility subleases																																	0	0	0	3,480,000
proceeds from issuance of common stock																																								0	190,428,000			0	0	85,228,000
proceeds from issuance of note hedge warrants																																					0
purchase of convertible note hedges
disposals under capital leases
write-down of inventory to net realizable value and loss on non-cancelable purchase commitments
principal payments on debt
write-down of inventory to net realizable value
proceeds from issuance of notes payable																																										0	175,000,000
costs associated with issuance of notes payable
supplemental cash flow disclosures:
payments on borrowings
income from discontinued operations
income from continuing operations
net cash from operating activities from continuing operations
net cash from operating activities from discontinued operations
total net cash from operating activities
proceeds from sale of subsidiary
net cash from investing activities from continuing operations																																															45,485,000	18,830,000	25,207,000
net cash from investing activities from discontinued operations
total net cash from investing activities																																															45,485,000	18,830,000	25,207,000
proceeds from initial public offering																																																		0	-1,000	203,168,000
proceeds from exercise of stock options, stock purchase plan and issuance of restricted stock																																															625,000
net cash from financing activities from continuing operations																																															565,000	1,349,000	599,000
net cash from financing activities from discontinued operations
debt and interest paid by purchases of subsidiary
proceeds from exercise of stock options and issuance of restricted stock																																																	675,000	749,000	112,000	354,000
remeasurement of forward purchase contracts
proceeds from the sale of property and equipment																																																			0	1,000
proceeds from issuance of preferred stock, net of issuance costs
proceeds from borrowings
debt and interest paid by purchaser of subsidiary
fair value of forward purchase contract
settlement of forward purchase contract related to forest agreement
net decrease in cash and cash equivalents

We provide you with 20 years of cash flow statements for Ironwood Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ironwood Pharmaceuticals stock. Explore the full financial landscape of Ironwood Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Ironwood Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.